Morden N E, Schpero W L, Zaha R, Sequist T D, Colla C H
The Dartmouth Institute for Health Policy & Clinical Practice, 35 Centerra Parkway, Lebanon, NH, 03766, USA,
Osteoporos Int. 2014 Sep;25(9):2307-11. doi: 10.1007/s00198-014-2725-2. Epub 2014 May 9.
We evaluated the prevalence and geographic variation of short-interval (repeated in under 2 years) dual-energy X-ray absorptiometry tests (DXAs) among Medicare beneficiaries. Short-interval DXA use varied across regions (coefficient of variation = 0.64), and unlike other DXAs, rates decreased with payment cuts.
The American College of Rheumatology, through the Choosing Wisely initiative, identified measuring bone density more often than every 2 years as care "physicians and patients should question." We measured the prevalence and described the geographic variation of short-interval (repeated in under 2 years) DXAs among Medicare beneficiaries and estimated the cost of this testing and its responsiveness to payment change.
Using 100 % Medicare claims data, 2006-2011, we identified DXAs and short-interval DXAs for female Medicare beneficiaries over age 66. We determined the population rate of DXAs and short-interval DXAs, as well as Medicare spending on short-interval DXAs, nationally and by hospital referral region (HRR).
DXA use was stable 2008-2011 (12.4 to 11.5 DXAs per 100 women). DXA use varied across HRRs: in 2011, overall DXA use ranged from 6.3 to 23.0 per 100 women (coefficient of variation = 0.18), and short-interval DXAs ranged from 0.3 to 8.0 per 100 women (coefficient of variation = 0.64). Short-interval DXA use fluctuated substantially with payment changes; other DXAs did not. Short-interval DXAs, which represented 10.1 % of all DXAs, cost Medicare approximately US$16 million in 2011.
One out of ten DXAs was administered in a time frame shorter than recommended and at a substantial cost to Medicare. DXA use varied across regions. Short-interval DXA use was responsive to reimbursement changes, suggesting carefully designed policy and payment reform may reduce this care identified by rheumatologists as low value.
我们评估了医疗保险受益人中短间隔(在2年内重复进行)双能X线吸收测定法(DXA)检查的患病率及地理差异。短间隔DXA的使用情况在各地区有所不同(变异系数 = 0.64),并且与其他DXA不同,其使用率会随着支付削减而下降。
美国风湿病学会通过“明智选择”倡议,将每两年内频繁测量骨密度确定为“医生和患者应质疑”的医疗行为。我们测量了医疗保险受益人中短间隔(在2年内重复进行)DXA检查的患病率,描述了其地理差异,并估算了这种检查的费用及其对支付变化的反应。
利用2006 - 2011年100%的医疗保险理赔数据,我们确定了66岁以上女性医疗保险受益人的DXA检查和短间隔DXA检查情况。我们确定了全国以及按医院转诊区域(HRR)划分的DXA检查和短间隔DXA检查的人口比率,以及医疗保险在短间隔DXA检查上的支出。
2008 - 2011年DXA的使用情况稳定(每100名女性中有12.4至11.5次DXA检查)。DXA的使用在各HRR之间存在差异:2011年,总体DXA使用率为每100名女性6.3至23.0次(变异系数 = 0.18),短间隔DXA使用率为每100名女性0.3至8.0次(变异系数 = 0.64)。短间隔DXA的使用随支付变化波动很大;其他DXA则不然。短间隔DXA检查占所有DXA检查的10.1%,2011年医疗保险为此花费约1600万美元。
十分之一的DXA检查是在短于推荐时间的框架内进行的,给医疗保险带来了巨大成本。DXA的使用在各地区存在差异。短间隔DXA的使用对报销变化有反应,这表明精心设计的政策和支付改革可能会减少风湿病学家认定为低价值的这种医疗行为。